Search research articles
Contact Us
Filters
Showing results (61-70 of 90) with videos related to
Page
of 9
Sort By:
British Journal of Cancer
|
February 23, 2022
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C
Amelie de Gregorio, Wolfgang Janni, Thomas W P Friedl, et al.
Geburtshilfe Und Frauenheilkunde
|
September 4, 2024
Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability - Real-World Data from German Breast Centers
Henning Schäffler, Dorothee Jakob, Sophia Huesmann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 28, 2023
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer
Peter A Fasching, Thomas Decker, Andreas Hartkopf, et al.
Archives of Gynecology and Obstetrics
|
April 22, 2025
Therapy of early breast cancer: current status and perspectives
Nikolas Tauber, Niklas Amann, Dominik Dannehl, et al.
Breast (Edinburgh, Scotland)
|
May 22, 2025
Clinical genome sequencing in patients with hereditary breast and ovarian cancer: Concept, implementation and benefits
Dennis Witt, Marc Sturm, Antje Stäbler, et al.
JAMA Oncology
|
May 11, 2023
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial
Oleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
Monika Graeser, Oleg Gluz, Peter Schmid, et al.
JCO Precision Oncology
|
February 17, 2022
Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer
Amelie De Gregorio, Thomas W P Friedl, Jens Huober, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 10, 2022
Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches
Cristiana Roggia, Sorin Armeanu-Ebinger, Axel Gschwind, et al.
Archives of Gynecology and Obstetrics
|
March 24, 2017
Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network
Carlo Fremd, Carolin C Hack, Andreas Schneeweiss, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 90) with videos related to
Sort By:
Page
of 9
British Journal of Cancer
|
February 23, 2022
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C
Amelie de Gregorio, Wolfgang Janni, Thomas W P Friedl, et al.
Geburtshilfe Und Frauenheilkunde
|
September 4, 2024
Novel Antibody-Drug-Conjugates in Routine Clinical Practice for the Treatment of Metastatic Breast Cancer: Adherence, Efficacy and Tolerability - Real-World Data from German Breast Centers
Henning Schäffler, Dorothee Jakob, Sophia Huesmann, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 28, 2023
Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer
Peter A Fasching, Thomas Decker, Andreas Hartkopf, et al.
Archives of Gynecology and Obstetrics
|
April 22, 2025
Therapy of early breast cancer: current status and perspectives
Nikolas Tauber, Niklas Amann, Dominik Dannehl, et al.
Breast (Edinburgh, Scotland)
|
May 22, 2025
Clinical genome sequencing in patients with hereditary breast and ovarian cancer: Concept, implementation and benefits
Dennis Witt, Marc Sturm, Antje Stäbler, et al.
JAMA Oncology
|
May 11, 2023
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor-Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial
Oleg Gluz, Ulrike A Nitz, Matthias Christgen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2025
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial
Monika Graeser, Oleg Gluz, Peter Schmid, et al.
JCO Precision Oncology
|
February 17, 2022
Discordance in Human Epidermal Growth Factor Receptor 2 (HER2) Phenotype Between Primary Tumor and Circulating Tumor Cells in Women With HER2-Negative Metastatic Breast Cancer
Amelie De Gregorio, Thomas W P Friedl, Jens Huober, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 10, 2022
Germline findings in patients with advanced malignancies screened with paired blood-tumour testing for personalised treatment approaches
Cristiana Roggia, Sorin Armeanu-Ebinger, Axel Gschwind, et al.
Archives of Gynecology and Obstetrics
|
March 24, 2017
Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network
Carlo Fremd, Carolin C Hack, Andreas Schneeweiss, et al.
Page
of 9